This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of the claims:

Claim 1: (previously canceled)

Claim 2: (previously amended) A method of diagnosing hereditary non-polyposis colorectal cancer in a patient comprising:

(a) obtaining a DNA or RNA sample from a patient; and

(b) screening the DNA or RNA sample with the oligonucleotide probe of claim 9 to detect a hMLH1 mutant 1, a hMSH2 mutant 1, a hMSH2 mutant 2, or a hMSH2 mutant 3, wherein binding of the oligonucleotide probe to the DNA or RNA sample is indicative of the presence of the hMLH1 mutant 1, the hMSH2 mutant 1, the hMSH2 mutant 2, or the hMSH2 mutant 3 and hereditary non-polyposis colorectal cancer.

Claim 3: (previously amended) A method for predicting susceptibility of a patient to developing hereditary non-polyposis colorectal cancer comprising:

(a) obtaining a DNA or RNA sample from a patient; and

(b) screening the DNA or RNA sample with the oligonucleotide probe of claim 9 to detect a hMLH1 mutant 1, a hMSH2 mutant 1, a hMSH2 mutant 2, or a hMSH2 mutant 3, wherein binding of the

oligonucleotide probe to the DNA or RNA sample is indicative of the presence of the hMLH1 mutant 1, the hMSH2 mutant 1, the hMSH2 mutant 2, or the hMSH2 mutant 3 and hereditary non-polyposis colorectal cancer.

Claims 4-8 (canceled)

Claim 9: (currently amended) An oligonucleotide probe ~~complementary to~~ capable of binding to a DNA or RNA sample and indicating the presence of a hMLH1 mutant 1, hMSH2 mutant 1, hMSH2 mutant 2, or hMSH2 mutant 3 in the sample.